American Journal of Obstetrics and Gynecology
Early Medical AbortionManagement of side effects and complications in medical abortion☆,☆☆
Section snippets
Comparison of Complications Between Medical and Surgical Abortion
In a report of 170,000 first-trimester surgical abortions performed by experienced abortion providers in the United States the overall complication rate among women with follow-up was 9 events/1000 procedures.2 Although rare, some of the most serious complications associated with surgical abortion, such as uterine perforation or complications of anesthesia, result directly or indirectly from the need to instrument the uterus. Successful medical abortion avoids these types of complications; in
Pain
Pain derives from noxious sensory stimulation at its site of origin but is moderated significantly by other factors, including fear and anxiety. Individual and cultural variations affect pain thresholds and the experience and expression of pain. Some women seeking abortion may have underlying emotional pain associated with an unintended pregnancy and its ramifications. Provision of full preliminary information helps patients to manage their pain response. Women who receive a description of the
Follow-up
After initiation of medical abortion treatment, follow-up is necessary to ensure complete abortion. Studies demonstrate that women may be unable to judge correctly on the basis of symptoms whether abortion has occurred. In clinical trials with methotrexate and misoprostol only about half of the women who thought that abortion had occurred actually had completed abortions at that time.11 Moreover, women may have symptom resolution consistent with a complete medical abortion yet still have a
Comment
Any medical procedure will have side effects and complications. Medical abortion, like surgical abortion, is a safe option for women with an unwanted pregnancy. Approximately 2% to 10% of women who have a medical abortion will require a surgical procedure for completion because of a continuing pregnancy, incomplete abortion, or the need for hemostasis. Although gastrointestinal and thermoregulatory side effects may occur, they generally are tolerable and short in dura-tion. Clinicians providing
References (75)
- et al.
Methotrexate and misoprostol for early abortion: a multicenter trial. Acceptability
Contraception
(1996) - et al.
Low-dose mifepristone 200mg and vaginal misoprostol for abortion
Contraception
(1999) - et al.
Methotrexate and misoprostol for early abortion: a multicenter trial. I. Safety and efficacy
Contraception
(1996) - et al.
Medical abortion with oral methotrexate and vaginal misoprostol
Obstet Gynecol
(1997) - et al.
Analysis of failure in medical abortion
Contraception
(1996) Medical abortion in early pregnancy: a review of the evidence
Obstet Gynecol
(1997)- et al.
Success rates and estimation of gestational age for medical abortion vary with transvaginal ultrasonographic criteria
Am J Obstet Gynecol
(1999) - et al.
Side effects of mifepristone-misoprostol abortion versus surgical abortion: data from a trial in China, Cuba, and India
Contraception
(1999) - et al.
The efficacy and tolerance of mifepristone and prostaglandin in termination of pregnancy of less than 63 days gestation; UK Multicentre Study—final results
Contraception
(1997) - et al.
Effect of nonsteroidal anti-inflammatory drugs on the action of misoprostol in a regimen for early abortion
Contraception
(1997)
Blood loss with mifepristone-misoprostol abortion: measures from a trial in China, Cuba and India
Int J Gynecol Obstet
Medical abortion with methotrexate 75 mg intramuscularly and vaginal misoprostol
Contraception
Outcomes of suction curettage and mifepristone abortion in the United States: a prospective comparison study
Contraception
Safety, efficacy, and acceptability of medical abortion in China, Cuba, and India: a comparative trial of mifepristone-misoprostol versus surgical abortion
Am J Obstet Gynecol
Misoprostol for medical evacuation of early pregnancy failure
Obstet Gynecol
Rectal misoprostol in the prevention of postpartum hemorrhage: a placebo-controlled trial
Am J Obstet Gynecol
Oral misoprostol for third stage of labor: a randomized placebo-controlled trial
Obstet Gynecol
Rectally administered misoprostol for the treatment of postpartum hemorrhage unresponsive to oxytocin and ergometrine: a descriptive study
Obstet Gynecol
Methotrexate and misoprostol for early abortion
Contraception
Abortion induced with methotrexate and misoprostol: a comparison of various protocols
Contraception
A randomized trial comparing misoprostol three and seven days after methotrexate for early abortion
Am J Obstet Gynecol
Methotrexate for abortion at ≤42 days gestation
Contraception
Oral methotrexate and vaginal misoprostol for early abortion
Contraception
Life-threatening neutropenia following methotrexate treatment of ectopic pregnancy: a report of two cases
Obstet Gynecol
Antibiotics at the time of induced abortion: the case for universal prophylaxis based on a meta-analysis
Obstet Gynecol
A randomized trial of prophylactic doxycycline for curettage in incomplete abortion
Obstet Gynecol
Outcome of first-trimester exposure to low-dose methotrexate in eight patients with rheumatic disease
Am J Med
Misoprostol and congenital malformations [letter]
Lancet
Pregnancy outcome after exposure to misoprostol in Brazil: a prospective, controlled study
Reprod Toxicol
Mifepristone (RU486) alone or in combination with a prostaglandin analogue for termination of early pregnancy: a review
Fertil Steril
Immunohistochemical analysis of estrogen and progesterone receptors in fallopian tubes during ectopic pregnancy
Fertil Steril
Medical treatment of ectopic pregnancy with methotrexate
Fertil Steril
Analysis of three hundred fifteen ectopic pregnancies treated with single-dose methotrexate
Am J Obstet Gynecol
Rupture of ectopic pregnancy after medical therapy with methotrexate: a case series
J Emerg Med
Abortion complications: prevention and management
Complications of first-trimester abortion: a report of 170,000 cases
Obstet Gynecol
Acceptability of medical abortion in early pregnancy
Fam Plann Perspect
Cited by (0)
- ☆
The opinions expressed in this article do not necessarily reflect those of Planned Parenthood Federation of America, Inc.
- ☆☆
Reprint requests: National Abortion Federation, 1755 Massachusetts Ave NW, Suite 600, Washington, DC 20036.